MIRA Pharmaceuticals, Inc. (MIRA)
NASDAQ: MIRA · IEX Real-Time Price · USD
0.603
-0.056 (-8.54%)
At close: Jul 2, 2024, 3:57 PM
0.600
-0.002 (-0.40%)
After-hours: Jul 2, 2024, 5:21 PM EDT
MIRA Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
3
Market Cap
8.91M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMIRA News
- 8 days ago - MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing - PRNewsWire
- 15 days ago - MIRA Announces Positive Test Results - Benzinga
- 22 days ago - Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year - PRNewsWire
- 4 weeks ago - Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance - PRNewsWire
- 6 weeks ago - MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog - PRNewsWire
- 6 weeks ago - Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog - PRNewsWire
- 3 months ago - Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission - PRNewsWire
- 3 months ago - MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor - PRNewsWire